Other languages Biocept, Inc.

Equities

Delayed OTC Markets Other stock markets 15:02:01 2024-04-23 EDT			5-day change	1st Jan Change
0.0001 ^USD	0.00%		0.00%	-99.76%

04-26	Motion for Asset Sale Approved for Biocept, Inc.	CI
04-02	Motion for Asset Sale Approved for Biocept, Inc.	CI

Biocept, Inc. Filed for Bankruptcy	23-10-13
Biocept, Inc. Announces the Full Enrollment of 40 Subjects with Breast or Non-Small Cell Lung Cancer	23-09-21
Sector Update: Health Care Stocks Slipping Late Friday8 Afternoon	23-09-08
Sector Update: Health Care Stocks Slipping Friday Afternoon	23-09-08
Sector Update: Health Care	23-09-08
Biocept Signs Non-Exclusive Licensing Agreement With Plus Therapeutics on CNSide Tumor Cell Platform	23-09-08
Wall Street Set to Open Flat Friday as Investors Remain Wary of Potential Interest Rate Hike	23-09-08
Top Premarket Gainers	23-09-08
Plus Therapeutics, Inc. Enters into License Agreement with Biocept for Cerebrospinal Fluid Tumor Cell Enumeration Assay	23-09-08
Biocept, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14
Biocept Says Board Chair Faye Wilson Died	23-07-14
Biocept Names Antonino Morales as President, CEO	23-06-20
Biocept, Inc. Appoints Antonino Morales as Chief Executive Officer	23-06-20
Biocept, Inc. Announces Executive Changes	23-06-20
Top Midday Decliners	23-05-25
Biocept Prices $5 Million Offering of Common Stock, Warrants	23-05-25
Sector Update: Health Care Stocks Steady Premarket Monday	23-05-22
Traders Remain Focused on Debt-Ceiling Negotiations, Driving Muted Premarket Action for US Equity Futures	23-05-22
Biocept, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10
Biocept, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-17

No results for this search